Philadelphia, US — On May 5, Coreline Soft, a leading medical AI imaging company, announced that it will present the future of AI-powered integrated diagnostics in collaboration with Temple Health, a major healthcare institution based in Philadelphia, at the 2025 American Thoracic Society (ATS) International Conference, to be held in San Francisco this May.
Temple Health has adopted Coreline Soft’s 3-in-1 integrated solution, AVIEW LCS Plus, which enables the simultaneous detection of lung cancer, cardiovascular disease, and COPD from a single low-dose chest CT scan. The hospital’s use of this solution is already being recognized as an innovative healthcare model within the Philadelphia region, with AI imaging technology contributing to early detection of incidental findings, improved survival rates, and more proactive care planning.
“It aids the mission of the Temple Healthy Chest Initiative to streamline lung cancer screenings and identify chest conditions at earlier stages, when treatment is most effective,” said Gerard Criner, MD, Director of the Temple Lung Center. “With AI-based imaging programs, we can detect not only lung nodules but also previously undetected comorbidities that were often missed in conventional CT workflows, ultimately making a meaningful difference in patient outcomes.”
According to James Lee, General Manager of Coreline Soft’s North America office:
“Our partnership with Temple Health goes beyond simple product implementation. It represents a real-world demonstration of how AI can advance both public health innovation and clinical effectiveness across U.S. healthcare systems. The upcoming ATS 2025 session will highlight how AI in medical imaging can establish new standards—not just in diagnostics, but across policy, patient care, and hospital strategy.”
AVIEW LCS Plus is currently being adopted in national lung cancer screening projects across major European countries, including Germany and Italy, as well as across Asia. It is widely recognized as a pioneering AI platform for the ‘Era of Incidental Findings,’ gaining attention in academic journals and health policy reports alike.
By assisting clinical decision-making while also supporting healthcare policy, research, and hospital financial models, AVIEW LCS Plus is emerging as a comprehensive AI system for integrated chest diagnostics. This case is expected to serve as a landmark example of how AI can evolve from a diagnostic tool into a holistic platform for medical innovation—improving patient outcomes, enabling smarter care, and informing long-term public health strategies.
